PVLA · Palvella Therapeutics, Inc.
$124.15
-33.09 (-21.04%)
At close · Jul 20
Market Cap
$1.78B
Shares
14.34M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$124.15
Open$155.72
Day$123.97–157.55
52W$29.38–161.38
Avg vol 30d318K
Short int2.4M · 16.5% float · 6.3d
Short vol82%
Last earningsMay 7, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 2 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.66
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+17%
above
Price vs 50-day avg
−1%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
72%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+10%
trailing
6-month return
+43%
trailing
YTD return
+19%
this year
Relative strength
+36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $125 › 200d $106 — 50d above 200d
Institutional flow
Accumulating
10 of 182 funds reported for Jun 30 · net +12.1K sh shares · +3 new
Insider flow
Distributing
Net -$475.6K over 90 days · 100% sells
Short interest
Rising
16.50% of float · ▲ +13.9% MoM · 6.3 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
182 holders — near 1-yr high, broad support
Squeeze score
81
high risk · 0–100
Fundamentals
Revenue growth
+65%
Y/Y
EPS growth
+53%
Y/Y
Free cash flow
$-25.2M
Balance sheet
$58.0M
net cash
Quant / Vol
risk profile
Volatility
85%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
8.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+17%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
72%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $125 › 200d $106 — 50d above 200d
Institutional flow
Accumulating
10 of 182 funds reported for Jun 30 · net +12.1K sh shares · +3 new
Insider flow
Distributing
Net -$475.6K over 90 days · 100% sells
Short interest
Rising
16.50% of float · ▲ +13.9% MoM · 6.3 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
182 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $29
Now $124 · 72%
52-wk high $161
vs 200-day avg +17%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PVLA
this stock
Palvella Therapeutics, Inc.
|
$1.78B | +18.6% | +65.3% | — | 16.5% |
|
ONC
BeOne Medicines Ltd.
|
$448.86B | +2.2% | +22179.2% | 913.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.95B | +6.0% | +46.2% | 28.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.47B | -12.8% | +20.8% | 16.4 | 3.3% |
|
ARGX
Argenx SE
|
$54.72B | +4.0% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PVLA | -15.0% | +9.8% | +42.7% | -18.8% | +18.6% |
| SPY | -1.0% | -0.6% | +7.1% | -0.6% | +8.8% |
| vs SPY | -14.0% | +10.4% | +35.6% | -18.1% | +9.8% |
Key facts
CIK
1583648
CUSIP
697947109
13F (30d)
10 filings
10 filers
Visit website
Investor relations